![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/17/2914290/0/en/Nouscom-Appoints-Tiffany-Muller-as-Chief-Financial-Officer-and-Loredana-Siani-as-Senior-Vice-President-Technical-and-CMC-Development.html
https://www.globenewswire.com/news-release/2024/05/14/2881071/0/en/Nouscom-Appoints-Leading-Cancer-Drug-Development-Expert-Neil-Gallagher-MD-PhD-as-Independent-Advisor-to-its-Board-and-Chair-of-its-R-D-Committee.html
https://www.globenewswire.com/news-release/2024/03/21/2849924/0/en/Angelini-Ventures-invests-into-extended-75-8-million-82-million-Series-C-financing-round-for-Nouscom-a-clinical-stage-immuno-oncology-company-developing-off-the-shelf-and-personali.html
https://endpts.com/swiss-cancer-vaccine-biotech-nouscom-raises-72m-series-c-for-phii-trials/
https://www.globenewswire.com//news-release/2023/10/31/2770247/0/en/Nouscom-s-Off-the-Shelf-Cancer-Vaccine-NOUS-209-Shows-Potential-to-Intercept-Cancer-in-Subjects-with-Lynch-Syndrome.html
https://www.indianpharmapost.com/news/nouscom-reaches-clinical-phase-ii-using-probiogens-age1crpix-production-platform-14093
https://www.globenewswire.com/news-release/2023/03/15/2627377/0/en/Nouscom-Announces-AACR-2023-Late-Breaking-Presentation-of-Translational-Phase-1b-Data-of-NOUS-PEV-a-Personalized-Neoantigen-Cancer-Immunotherapy.html
https://www.prnewswire.com/news-releases/nouscom-announces-clinical-trial-collaboration-and-supply-agreement--with-msd-to-evaluate-nous-209-in-combination-with-keytruda-pembrolizumab-in-a-phase-2-randomized-trials-in-dmmrmsi-high-metastatic-colorectal-cancer-301714117.html
https://www.prnewswire.com/news-releases/nouscom-announces-first-patient-dosed-in-phase-2-randomized-trial-with-nous-209-an-off-the-shelf-neoantigen-cancer-immunotherapy-in-dmmrmsi-high-metastatic-colorectal-cancer-301677906.html
https://www.prnewswire.com/news-releases/nouscom-announces-leading-publication-revealing-an-immune-mechanism-of-action-driving-anti-tumor-activity-of-adenovirus-vectored-vaccines-and-anti-pd1-immunotherapy-301603813.html